Also, our findings demonstrate that HDAC2 up-regulation protected CML cells resistant to IM from apoptosis as well as cell cycle arrest at the G2/M phase induced by the combined treatment. Here, HDAC2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.